Latest Content

Six-time cancer survivor encourages patients to trust doctors, lean on support, and save energy for moving forward instead of fear.

The U.S. FDA has granted orphan drug designation to HCB101, an investigational immunotherapy, for the treatment of gastric cancer.

There are a number of pulmonary embolism warning signs patients with cancer and their caregivers should watch for.

Phase 2 study shows proton therapy kept 79.1% of patients progression free at five years and limited severe side effects compared with older radiation data.

Exploring the importance of heart health in cancer survivorship, we spoke with experts and survivors.

Heather Quintana Suchan says early biomarker testing at diagnosis helped match her to Rybrevant and urges patients to personalize care and stay active during treatment.

A liver cancer survivor shares transplant insights, dispels living donor myths and urges patients to advocate for informed, hopeful care.

Heather Quintana Suchan, a nonsmoker with stage 4 lung cancer, credits genomic testing and Rybrevant and urges others not to ignore mild symptoms.

A three-time cervical cancer survivor urges patients with cancer to be thorough, seek multiple opinions and trust their gut to find providers who listen, validate concerns and truly support them.

A Clayman Thyroid Center report aims to clarify FDA safety warnings, finding no evidence that GLP-1 drugs like Ozempic cause common thyroid cancers.

The FDA has accepted a sNDA for Ameluz topical gel, used in combination with the RhodoLED red-light lamp series, for superficial basal cell carcinoma treatment.

The U.S. Food and Drug Administration has approved a new treatment for adults with locally advanced pancreatic cancer.

Colleen Mabasa reflected on the importance of self-advocacy, as well as seeking second opinions and ensuring patients understand all available options.